Literature DB >> 1581913

The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression.

A Borg1, Q X Zhang, P Alm, H Olsson, G Sellberg.   

Abstract

The significance of the retinoblastoma gene (RB) in the development of human breast cancer remains unclear. In the present study, loss of heterozygosity (LOH) in RB was found in 26% of 90 informative primary breast tumors and was correlated to DNA nondiploidy, a high S-phase fraction, and LOH at chromosome 17p13.3. However, allele loss was not associated with loss of RB protein (pRB) expression. Low to absent levels of pRB were found in 15% of 73 immunoblot analyzed tumors, most of which manifested retained heterozygosity in RB. Conversely, tumors exhibiting LOH showed often high pRB expression. Our data suggest that RB may be involved in the pathogenesis of some breast tumors, as evidenced by the absence of pRB, but that this alteration is acquired by mechanisms other than the unmasking of a recessive mutation by allele loss. LOH in RB may be merely a stochastic event in the unstable genome of aneuploid, rapidly proliferating cells or, alternatively, reflect the presence of an adjacent tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1581913

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma.

Authors:  K Ashida; Y Kishimoto; K Nakamoto; K Wada; G Shiota; Y Hirooka; Y Kamisaki; T Itoh; H Kawasaki
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 2.  Surprising dependency for retinoblastoma protein in ras-mediated tumorigenesis.

Authors:  James DeGregori
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

3.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

4.  RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Cell Cycle       Date:  2010-12-01       Impact factor: 4.534

5.  Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer.

Authors:  E Wakasugi; T Kobayashi; Y Tamaki; Y Nakano; Y Ito; I Miyashiro; Y Komoike; M Miyazaki; T Takeda; T Monden; M Monden
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

6.  Altered structure and expression of RB1 gene and increased phosphorylation of pRb in human vestibular schwannomas.

Authors:  R Thomas; P D Antony Herold Prabhu; J Mathivanan; D Sivakumar; P N Jayakumar; B Indira Devi; S Satish; K V R Sastry; R Gope
Journal:  Mol Cell Biochem       Date:  2005-03       Impact factor: 3.396

7.  Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.

Authors:  V G Gorgoulis; E N Koutroumbi; A Kotsinas; P Zacharatos; C Markopoulos; L Giannikos; V Kyriakou; Z Voulgaris; I Gogas; C Kittas
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

8.  Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer.

Authors:  J S de Jong; P J van Diest; R J Michalides; P van der Valk; C J Meijer; J P Baak
Journal:  Mol Pathol       Date:  1998-02

9.  Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.

Authors:  Elisabet Ognedal Berge; Stian Knappskog; Stephanie Geisler; Vidar Staalesen; Marec Pacal; Anne-Lise Børresen-Dale; Pål Puntervoll; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  Mol Cancer       Date:  2010-07-01       Impact factor: 27.401

10.  The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.

Authors:  Jason I Herschkowitz; Xiaping He; Cheng Fan; Charles M Perou
Journal:  Breast Cancer Res       Date:  2008-09-09       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.